Loading...
•
Dec 31, 2024
Kymera Therapeutics Q4 2024 Earnings Report
Reported financial results for the fourth quarter and full year ended December 31, 2024, and provided business highlights and updates on its pipeline.
Key Takeaways
Kymera Therapeutics reported collaboration revenues of $7.4 million for Q4 2024. The company's research and development expenses were $71.8 million, and general and administrative expenses were $16.3 million. Net loss for the quarter was $70.8 million. The company's cash and cash equivalents totaled $851 million as of December 31, 2024.
KT-621 Phase 1 healthy volunteer trial ongoing, complete SAD/MAD data expected in June 2025.
KT-621 Phase 1b trial in atopic dermatitis (AD) patients expected to initiate in 2Q25 with data in 4Q25, followed by two parallel Phase 2b trials in AD and asthma starting in 4Q25 and 1Q26, respectively.
KT-295 (TYK2) Phase 1 trial is expected to start in 2Q25, with data expected in 4Q25.
Well-capitalized with $851 million in cash as of December 31, 2024, and runway into mid-2027.
Forward Guidance
Kymera anticipates a cash runway into mid-2027.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...